3 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Terminated 1 |
Follow MK-0249: new trials by email Literature Review of MK-0249 trials Research Report on MK-0249
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023) MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg - Alzheimer's Disease, Dementia | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 4 | 2009-04-06 | 2018-10-17 |
| MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) MK0249, Comparator: Placebo (unspecified) - Paranoid Schizophrenia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 55 | 2007-12-01 | 2015-08-03 |
| A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) MK0249, Concerta (methylphenidate), Placebo - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 | Completed | Merck Sharp & Dohme LLC | 72 | 2007-07-01 | 2015-07-28 |
| MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) MK0249, Comparator: Placebo (unspecified) - Alzheimer's Disease | Phase 2 | Completed | Merck Sharp & Dohme LLC | 144 | 2006-11-01 | 2015-02-12 |
Alzheimer Disease (2) · Attention Deficit Disorder with Hyperactivity (1) · Dementia (1) · Schizophrenia, Paranoid (1)